---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-22-000086"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:09:47.189998+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio CEO Thomas Isett resigns; interim office of CEO created with Lutz and Brenner

## Summary
- CEO Thomas Isett resigned effective Dec 1, 2022; no disagreement with strategy or policies.
- Isett will receive severance: 24 months base salary, pro-rata target bonus, plus COBRA coverage for 18 months.
- Board created Office of the CEO, with CFO Robert Lutz and CSO Dr. Martin Brenner filling the role.
- Leadership team reports to Board Chair William (Chip) Clark while search for new CEO continues.
- Isett remains employee until Dec 31, 2022; will assist with CDMO sale through March 2023.

## SEC filing metadata
- accession: 0001420720-22-000086
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/ibio-20221201x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-22-000086
- JSON: https://secwatch.observer/filing/0001420720-22-000086.json
- Plain text: https://secwatch.observer/filing/0001420720-22-000086.txt

## Key facts
- Executive change
  Robert Lutz was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..
  - Action: appointed
  - Role: Office of the Chief Executive Officer (joint)
  source text: the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm
- Executive change
  Thomas F. Isett resigned as Chief Executive Officer at iBio, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Mr. Isett resigned as CEO of the Company effective December 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm
- Executive change
  Martin Brenner was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..
  - Action: appointed
  - Role: Office of the Chief Executive Officer (joint)
  source text: the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.